Findings from Abraxis BioScience phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab(R)) driven chemotherapy, nab-paclitaxel (Abraxane for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
James McKiernan, director of urologic oncology, department of urology, Herbert Irving Comprehensive Cancer Center, Columbia University, said: “The preliminary results of this study suggest nab-paclitaxel may have a potential benefit for high-risk non-muscle-invasive bladder cancer patients who have failed prior intravesical treatment or who are unable or unwilling to undergo cystectomy.”
Patrick Soon-Shiong, executive chairman and founder of Abraxis BioScience, said: “The promising results of Abraxane in the treatment of patients with bladder cancer support the efficacy of nab-driven chemotherapy across an increasing range of advanced and difficult-to-treat cancers.
“This study further supports our commitment to develop a deeper understanding of how albumin-bound Abraxane’s unique affinity for the secreted protein Sparc may enable targeted cytoxotic agents to be delivered directly into the tumor microenvironment, supporting better patient outcomes.”